Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

(2018) A Sobrero et al.   ANNALS OF ONCOLOGY

FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial

(2018) Alberto Sobrero et al.   JOURNAL OF CLINICAL ONCOLOGY

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial

(2018) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

(2018) Timothy J Iveson et al.   LANCET ONCOLOGY

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

(2018) Axel Grothey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Should the Benefit of Adjuvant Chemotherapy in Colon Cancer Be Re-Evaluated?

(2016) Lars A. Påhlman et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According toBRAFMutation and Mismatch Repair Status of the MOSAIC Study

(2015) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials

(2014) Hans-Joachim Schmoll et al.   LANCET ONCOLOGY